KALAMAZOO, Mich., Feb. 24, 2016 /PRNewswire/ — AureoGen Biosciences Inc. today announced a licensing agreement with Merck, known as MSD outside the United States and Canada, for the use of AureoGen’s proprietary chemistry and compounds for the development of medicines for infectious disease, including systemic fungal infections.